SPG Block for Acute Pediatric Migraine

Sphenopalatine Ganglion Block for Treating Acute Frontal Migraine Headache in Pediatric Patients

This is a randomized double blind trial comparing an intranasal sphenopalatine block with 2% lidocaine to intravenous (0.15 mg/kg, max 10mg) prochlorperazine in patients greater than 10 years of age presenting to a pediatric emergency department with an acute frontal migraine headache.

This is a randomized double blind trial comparing an intranasal sphenopalatine block with 2% lidocaine to intravenous (0.15 mg/kg, max 10mg) prochlorperazine in patients greater than 10 years of age presenting to a pediatric emergency department with an acute frontal migraine headache. Excluded populations include those with sickle cell, concern for CNS infection

Inclusion Criteria:

- Frontal migraine headache

Exclusion Criteria:

• Non-english speaking
• Known pregnancy
• Sickle cell hemaglobinopathy
• Concern for CNS infection
• Acute febrile illness
• non-frontal headaches
• Concern for increased intracranial pressure